We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+3.73%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$366M
AUM Growth
-$32.5M
Cap. Flow
-$24.7M
Cap. Flow %
-6.75%
Top 10 Hldgs %
88.66%
Holding
26
New
2
Increased
4
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$10.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$5.36M
3
TRVN
Trevena, Inc.
TRVN
+$3.97M
4
NERV icon
Minerva Neurosciences
NERV
+$1.59M
5
DVAX
Dynavax Technologies
DVAX
+$35.4K

Top Sells

Rank Stock Value
1
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$32.5M
2
KITE
Kite Pharma, Inc.
KITE
+$8.87M
3
LITS
Lite Strategy Inc
LITS
+$2.34M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$2.21M
5
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$55.5K

Sector Composition

Rank Sector Weight
1 Healthcare 66.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGNT
1
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$97.3M 26.57%
6,495,416
-4,321
-0.1% -$55.5K
ACRS icon
2
Aclaris Therapeutics
ACRS
$744M
$77.4M 21.14%
4,191,397
– –
EIGR
3
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$31.7M 8.66%
53,320
– –
NBRV
4
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$23.6M 6.46%
12,607
– –
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
$23.4M 6.4%
1,766,832
+347,500
+24% +$5.36M
CDXS icon
6
Codexis
CDXS
$136M
$22.5M 6.13%
5,573,319
– –
AGRX
7
DELISTED
Agile Therapeutics
AGRX
$15.4M 4.2%
1,010
– –
AAAP
8
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$13.8M 3.76%
455,798
– –
TRVN
9
DELISTED
Trevena, Inc.
TRVN
$10.9M 2.97%
2,765
+845
+44% +$3.97M
SLNO
10
DELISTED
Soleno Therapeutics
SLNO
$8.65M 2.36%
99,426
-125
-0.1% -$11.4K
AIMT
11
DELISTED
Aimmune Therapeutics
AIMT
$8.26M 2.25%
+763,009
New +$10.4M
RGNX icon
12
Regenxbio
RGNX
$615M
$7.92M 2.16%
990,449
– –
AKTX
13
Akari Therapeutics
AKTX
$14.8M
$7.12M 1.94%
660
– –
DVAX
14
DELISTED
Dynavax Technologies
DVAX
$5.25M 1.43%
359,828
+2,073
+0.6% +$35.4K
SRRA
15
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.85M 1.33%
60,957
– –
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$2.77M 0.76%
300,326
– –
NERV icon
17
Minerva Neurosciences
NERV
$199M
$2.04M 0.56%
+25,000
New +$1.59M
LITS
18
Lite Strategy Inc
LITS
$33M
$1.5M 0.41%
55,056
-83,330
-60% -$2.34M
RVNC
19
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.05M 0.29%
77,373
– –
OCRX
20
DELISTED
Ocera Therapeutics, Inc.
OCRX
$291K 0.08%
153,331
– –
CAPNW
21
DELISTED
Capnia, Inc. Series A Warrant
CAPNW
$245K 0.07%
943,858
+10,948
+1% +$2.83K
ZSAN
22
DELISTED
Zosano Pharma Corporation
ZSAN
$125K 0.03%
141
– –
PTN
23
Palatin Technologies
PTN
$13.7M
$103K 0.03%
188
– –
CCXI
24
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-887,906
Closed -$2.21M
KITE
25
DELISTED
Kite Pharma, Inc.
KITE
– –
-193,193
Closed -$8.87M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Vivo Capital held 26 positions worth $366M, down 8.2% from $399M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Vivo Capital withdrew a net $24.7M in Q2 2016, closing 3 positions and reducing 3 holdings. Its most notable exit was BIOTIE THERAPIES CORP SPONSORED ADR, an estimated $32.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 66% a quarter earlier.

Against the trend, Vivo Capital opened a new position in Aimmune Therapeutics worth $8.26M.

  • Vivo Capital's largest Q2 2016 buy was Aimmune Therapeutics: 763,009 shares worth $8.26M.
  • Vivo Capital added most to Ascendis Pharma A/S in Q2 2016, an estimated $5.36M increase.
  • Vivo Capital's biggest Q2 2016 reduction was Lite Strategy Inc, cutting an estimated $2.34M.
  • Vivo Capital fully exited BIOTIE THERAPIES CORP SPONSORED ADR in Q2 2016, selling an estimated $32.5M.
  • Vivo Capital's ten largest holdings make up 89% of its $366M portfolio in Q2 2016.
  • Vivo Capital opened 2 new positions and closed 3 in Q2 2016.
  • Vivo Capital's portfolio value fell 8.2% quarter-over-quarter to $366M.

Based on Vivo Capital's 13F filing for Q2 2016, filed 15 Aug 2016.